GlassScriptPhysician profile
Mary K Gingrass
NPI 1518959931
$15,445.08
in general payments reported to CMS, 2019-2025
11 companies · $855 in 2025
The $855 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,363 · 2020: $290 · 2021: $253 · 2022: $4,268 · 2023: $184 · 2024: $1,232 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.32 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12,721.59 | 2019-2022 | |
| Motiva USA, LLC | $1,393.90 | 2024-2025 | |
| Abbvie INC. | $522.54 | 2023-2025 | |
| Sientra, INC. | $344.14 | 2019-2022 | |
| Mentor Worldwide LLC | $134.79 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Davol INC. | $134.05 | 2025 | Phasix Mesh |
| Galderma Laboratories, L.P. | $74.98 | 2019-2023 | Dysport |
| Musculoskeletal Transplant Foundation INC. | $36.52 | 2025 | |
| Stryker Corporation | $34.03 | 2025 | Inspace, Spy-Phi System |
| Abbott Laboratories | $32.61 | 2023 | |
| Integra Lifesciences Corporation | $15.93 | 2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Gingrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.